Qubigen Partners with GigCity to Power Next‑Gen AI Drug Discovery
- David Brooks
- Aug 4
- 2 min read
Qubigen is proud to announce its collaboration with GigCity, a Government of South Australia initiative delivering ultra-fast, affordable gigabit internet across innovation precincts in Adelaide. This partnership is central to Qubigen’s mission to drive secure, Federated AI drug design, where large-scale data processing and rapid global collaboration are essential.
Why GigCity Matters to AI‑Enabled Drug Design
Qubigen’s platform requires frequent uploads and downloads of massive molecular datasets, virtual screening results, and AI model checkpoints. Access to GigCity’s gigabit speeds and reliable connectivity has been essential in securely delivering this data to clients worldwide and powering uninterrupted AI workflows. While Qubigen’s Federated AI workflows process proprietary datasets at the source, where no data is transferred or exposed, GigCity enables Qubigen to orchestrate these distributed training jobs at speed and scale. Gigabit internet minimizes latency, supports real-time analytics, and ensures seamless virtual screening and quantum chemistry computations.
What It Means for Innovation in Adelaide and Beyond
This collaboration reinforces Adelaide’s emergence as a tech and biotech innovation hub, fueled by infrastructure and a culture of scientific excellence. With GigCity’s support, Qubigen is now operationally equipped to deploy Federated AI drug design to partners worldwide to solve difficult therapeutic challenges from its Australian headquarters. Qubigen continues to scale its AI drug discovery platform, combining federated learning with molecular mechanics and quantum chemistry to accelerate lead identification while preserving data privacy. With GigCity as a technical backbone, Qubigen is poised to deliver transformative outcomes for pharmaceutical and academic partners globally.
Find out more:
Â
Qubigen - accelerate drug design without exposing secrets
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.